Mitochondrial DNA (mtDNA) leakage into the cytoplasm can occur when cells are exposed to noxious stimuli. Specific sensors recognize cytoplasmic mtDNA to promote cytokine production. Cytoplasmic mtDNA can also be secreted extracellularly, leading to sterile inflammation. However, the mode of secretion of mtDNA out of cells upon noxious stimuli and its relevance to human disease remain unclear. Here, we show that pyroptotic cells secrete mtDNA encapsulated within exosomes. Activation of caspase-1 leads to mtDNA leakage from the mitochondria into the cytoplasm via gasdermin-D. Caspase-1 also induces intraluminal membrane vesicle formation, allowing for cellular mtDNA to be taken up and secreted as exosomes. Encapsulation of mtDNA within exosomes promotes a strong inflammatory response that is ameliorated upon exosome biosynthesis inhibition in vivo. We further show that monocytes derived from patients with Behçet's syndrome (BS), a chronic systemic inflammatory disorder, show enhanced caspase-1 activation, leading to exosome-mediated mtDNA secretion and similar inflammation pathology as seen in BS patients. Collectively, our findings support that mtDNA-containing exosomes promote inflammation, providing new insights into the propagation and exacerbation of inflammation in human inflammatory diseases.
Objectives: We evaluated the efficacy of Janus kinase inhibitors (JAKis) compared with TNF inhibitors (TNFis) in RA patients with poor-prognosis factors (PPFs), including ACPA or RF positivity, Clinical Disease Activity Index (CDAI) ≥22, CRP ≥0.6 mg/dl and HAQ-DI ≥0.5. We focused on treatment continuation, disease control and glucocorticoid (GC) reduction. Methods: We conducted a retrospective analysis of the ANSWER cohort, including 1794 RA patients treated with a TNFi (n = 1235) or JAKi (n = 559). Propensity score matching was applied to reduce bias. We categorized the patients into those with 4PPFs or <4 PPFs. Treatment persistence, CDAI changes and GC tapering over 24 months were analysed. Results: JAKi treatment demonstrated greater CDAI reduction (JAKi vs TNFi median: −23.3 vs −19.9), particularly in ACPA-positive patients. In the 4PPFs patients, JAKi treatment led to a significantly higher low disease activity achievement rate compared with TNFi (68.8% vs 60.9%) at 24 months. JAKi treatment also enabled faster GC tapering, with 72.4% discontinuation compared with 50.3% in the TNFi group at 24 months. Among the 4PPFs patients, JAKi treatment facilitated a greater (but nonsignificant) reduction in GC dosage over time. The cumulative GC discontinuation rate remained consistently higher in the JAKi group, reaching 61.3% vs 48.4% in the TNFi group at 24 months. Conclusions: JAKi treatment provided sustained disease control (especially in high-risk RA patients) and promoted GC reduction. Although TNFi remains a standard option, JAKi treatment may be preferable in patients with 4PPFs. Further research should evaluate JAKi treatment’s long-term safety and efficacy.
Objectives: This multicentre, retrospective study aimed to evaluate differences in drug continuation rates and efficacy between first- and second-line use of biological DMARDs (bDMARDs) and Janus kinase inhibitors (JAKi) after failure of the initial therapy in real-world RA settings. Methods: Data from an observational multicentre registry of patients with RA in Japan were analysed, encompassing 5900 treatment courses (4046 bDMARD/JAKi-naïve cases and 1854 second-line cases). Gray’s tests were used to compare the cumulative incidence function (CIF) for drug discontinuation, considering discontinuation due to remission as a competing risk. Competing risk analysis using Fine–Gray model was conducted to analyse the hazard ratios after adjusting for potential confounders. Changes in the Clinical Disease Activity Index (ΔCDAI) and disease activity score (ΔDAS28-CRP) were assessed at each time point compared with baseline using a linear mixed model with covariate adjustments. Results: Among the TNF inhibitors, IL-6 inhibitors, Cytotoxic T-lymphocyte associated protein 4 (CTLA4) and JAKi, only JAKi showed no significant difference in CIF of first- and second-line treatments. Competing risk analysis showed that consistent with the CIF analysis, second-line treatment influenced the drug continuation rates for all drugs except for JAKi. In analysing CDAI and DAS28-CRP trends using a linear mixed model, JAKi demonstrated similar efficacy as first- and second-line therapy, unlike other drugs. Conclusions: JAKi maintained continuation rates and efficacy in second-line treatment compared with first-line treatment, which is potentially advantageous over bDMARDs for patients with RA who require a change in initial therapy.